Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Bronchitis Therapeutics market. The report identifies the key trends shaping and driving the global Bronchitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bronchitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Bronchitis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Bronchitis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Bronchitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bronchitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Bronchitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Bronchitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bronchitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Bronchitis Therapeutics market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Bronchitis Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Forms of Bronchitis -
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Risk factors for Bronchitis
2.5 Signs and Symptoms
2.6 Prognosis:
2.7 Diagnosis
2.8 Referral Pathway
2.9 Treatment and Management Pattern
2.10 GlobalData Pipeline Report Guidance
3 Bronchitis Therapeutics - Market Characterization
3.1 Overview
3.2 Bronchitis Therapeutics Market Size (2005 - 2010) - Global
3.3 Bronchitis Therapeutics Market Forecast (2010 - 2018) - Global
3.4 Bronchitis Therapeutics Market Size (2005 - 2010) - The US
3.5 Bronchitis Therapeutics Market Forecast (2010 - 2018) - The US
3.6 Bronchitis Therapeutics Market Size (2005 - 2010) - France
3.7 Bronchitis Therapeutics Market Forecast (2010 - 2018) - France
3.8 Bronchitis Therapeutics Market Size (2005 - 2010) - Germany
3.9 Bronchitis Therapeutics Market Forecast (2010-2018) - Germany
3.10 Bronchitis Therapeutics Market Size (2005 - 2010) - Italy
3.11 Bronchitis Therapeutics Market Forecast (2010 - 2018) - Italy
3.12 Bronchitis Therapeutics Market Size (2005 - 2010) - Spain
3.13 Bronchitis Therapeutics Market Forecast (2010 - 2018) - Spain
3.14 Bronchitis Therapeutics Market Size (2005 - 2010) - The UK
3.15 Bronchitis Therapeutics Market Forecast (2010 - 2018) - The UK
3.16 Bronchitis Therapeutics Market Size (2005 - 2010) - Japan
3.17 Bronchitis Therapeutics Market Forecast (2010 - 2018) - Japan
3.18 Drivers and Barriers for the Bronchitis Therapeutics Market
3.18.1 Drivers for the Bronchitis Therapeutics Market
3.18.2 Barriers for the Bronchitis Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.19.1 Opportunity and Unmet Need in the Bronchitis Therapeutics Market
3.20 Key Takeaway
4 Bronchitis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Bronchitis Therapeutics Market
4.3.1 Spiriva HandiHaler (tiotropium bromide inhalation powder)
4.3.2 Foradil Aerolizer (formoterol fumarate inhalation powder)
4.3.3 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5µg
4.3.4 Advair Diskus (fluticasone propionate/salmeterol) 250/50µg
4.3.5 Arcapta/Onbrez Breezhaler (indacaterol maleate)
4.3.6 Daliresp (roflumilast) Tablet
4.3.7 Atrovent HFA (ipratropium bromide)
4.3.8 Combivent (ipratropium bromide and albuterol sulfate)
4.3.9 Antibiotics
4.4 Key Takeaway
5 Bronchitis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Bronchitis Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Bronchitis Therapeutics - NDA Filed Pipeline
5.3.2 Bronchitis Therapeutics - Phase III Clinical Pipeline
5.3.3 Bronchitis Therapeutics - Phase II/III Pipeline
5.3.4 Bronchitis Therapeutics - Phase II Clinical Pipeline
5.3.5 Bronchitis Therapeutics - Phase II/I Clinical Pipeline
5.3.6 Bronchitis Therapeutics - Phase I Pipeline
5.3.7 Bronchitis Therapeutics - Preclinical Pipeline
5.3.8 Bronchitis Therapeutics - Discovery Pipeline
5.4 Technology Trends Analytic Framework
5.5 Bronchitis Therapeutics Market - Pipeline by Mechanism of Action
5.6 Bronchitis Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 Eklira (aclidinium bromide)
5.7.2 Andolast (CR 2039)
5.7.3 Dulera
5.7.4 Erdosteine
5.7.5 Fluticasone + Formoterol
5.7.6 Glycopyrronium bromide (NVA237)
5.7.7 GSK573719
5.7.8 Olodaterol (BI 1744 CL)
5.7.9 QVA 149 (indacaterol and glycopyrrolate)
5.7.10 Relovair
5.7.11 Vilanterol (GW642444)
5.7.12 Vilanterol + GSK573719
5.7.13 Easyhaler Inhalation Corticosteroid/Beta Agonist Fixed Dose Combination
5.8 Key Takeaway
6 Bronchitis Therapeutics - Clinical Trials Mapping
6.1 Acute Bronchitis - Clinical Trials by Region/ Country
6.2 Acute Bronchitis - Clinical Trials by Phase
6.3 Acute Bronchitis - Clinical Trials by Trial Status
6.4 Acute Bronchitis - Sponsors
6.5 Acute Bronchitis - Top Companies Participating in Therapeutics Clinical Trials
6.6 Chronic Bronchitis - Clinical Trials by Region/ Country
6.7 Chronic Bronchitis - Clinical Trials by Phase
6.8 Chronic Bronchitis - Clinical Trials by Trial Status
6.9 Chronic Bronchitis - Sponsors
6.10 Chronic Bronchitis - Top Companies Participating in Therapeutics Clinical Trials
6.11 COPD - Clinical Trials by Region/ Country
6.12 COPD - Clinical Trials by Phase
6.13 COPD - Clinical Trials by Trial Status
6.14 COPD - Sponsors
6.15 COPD - Top Companies Participating in Therapeutics Clinical Trials
7 Bronchitis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition
8 Bronchitis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 GlaxoSmithKline
8.2.2 Novartis AG
8.2.3 AstraZeneca
8.2.4 Bronchitis Pipeline
8.2.5 Merck & Co.
8.2.6 Forest Laboratories, Inc.
8.2.7 Boehringer Ingelheim GmbH
8.2.8 Financial Overview
8.2.9 Almirall, S.A.
8.2.10 Orion Corporation
8.2.11 Rottapharm Madaus
8.2.12 Ache Laboratorios Farmaceuticos S/A
8.2.13 Other Companies in the Bronchitis Therapeutics Market
9 Bronchitis Therapeutics - Licensing and Partnership Deals
10 Bronchitis Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer

1.1 List of Tables
Table 1: Bronchitis Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 2: Bronchitis Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 3: Bronchitis Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 4: Bronchitis Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Table 5: Bronchitis Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 6: Bronchitis Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 7: Bronchitis Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 8: Bronchitis Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 9: Bronchitis Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 10: Bronchitis Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 11: Bronchitis Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 12: Bronchitis Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 13: Bronchitis Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 14: Bronchitis Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 15: Bronchitis Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 16: Bronchitis Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 17: Bronchitis Therapeutics - NDA Filed Pipeline, 2011
Table 18: Bronchitis Therapeutics - Phase III Clinical Pipeline, 2011
Table 19: Bronchitis Therapeutics - Phase II/III Clinical Pipeline, 2011
Table 20: Bronchitis Therapeutics - Phase II Clinical Pipeline, 2011
Table 21: Bronchitis Therapeutics - Phase II/I Clinical Pipeline, 2011
Table 22: Bronchitis Therapeutics - Phase I Clinical Pipeline, 2011
Table 23: Bronchitis Therapeutics - Preclinical Pipeline, 2011
Table 24: Bronchitis Therapeutics - Discovery Pipeline, 2011
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart
Table 26: Bronchitis Therapeutics Market - Promising Drugs Under Clinical Development, 2011
Table 27: Bronchitis Therapeutics Market, Clinical Trials by Indication, 2011
Table 28: Acute Bronchitis Therapeutics Market, Clinical Trials by Country, 2011
Table 29: Acute Bronchitis Therapeutics Market, Clinical Trials by Phase, 2011
Table 30: Acute Bronchitis Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 31: Acute Bronchitis Therapeutics Market - Clinical Trials by Sponsors, 2011
Table 32: Acute Bronchitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Table 33: Chronic Bronchitis Therapeutics Market, Clinical Trials by Country, 2011
Table 34: Chronic Bronchitis Therapeutics Market, Clinical Trials by Phase, 2011
Table 35: Chronic Bronchitis Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 36: Chronic Bronchitis Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Table 37: Chronic Bronchitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Table 38: COPD Therapeutics Market, Clinical Trials by Country, 2011
Table 39: COPD Therapeutics Market, Clinical Trials by Phase, 2011
Table 40: COPD Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 41: COPD Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Table 42: COPD Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Table 43: COPD Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Table 44: GlaxoSmithKline - Respiratory pipeline, 2011
Table 45: GlaxoSmithKline - Bronchitis pipeline, 2011
Table 46: Novartis AG - Respiratory pipeline, 2011
Table 47: Novartis AG- Bronchitis Pipeline, 2011
Table 48: AstraZeneca - Respiratory Pipeline, 2011
Table 49: AstraZeneca - Bronchitis Pipeline, 2011
Table 50: Merck & Co. - Respiratory Pipeline, 2011
Table 51: Merck & Co. - COPD Pipeline, 2011
Table 52: Forest Laboratories, Inc. - Respiratory pipeline, 2011
Table 53: Boehringer Ingelheim GmbH - Respiratory Pipeline, 2011
Table 54: Boehringer Ingelheim GmbH - COPD Pipeline, 2011
Table 55: Almirall, S.A. - Respiratory Pipeline, 2011
Table 56: Orion Corporation - Respiratory Pipeline, 2011
Table 57: Rottapharm Madaus - Respiratory Pipeline, 2011
Table 58: Rottapharm Madaus - COPD Pipeline, 2011
Table 59: Ache Laboratorios Farmaceuticos S/A - Respiratory Pipeline, 2011
Table 60: Bronchitis Therapeutics Market - Other Future Players, 2011
Table 61: Bronchitis Therapeutics Market, Licensing and Partnership Deals, 2011

1.2 List of Figures
Figure 1: Understanding Bronchitis
Figure 2: Normal and Infected Bronchi
Figure 3: Cause of Acute Bronchitis
Figure 4: Cause of Chronic Bronchitis
Figure 5: Etiology of Acute Bronchitis
Figure 6: Etiology of Chronic Bronchitis
Figure 7: Risk of Developing Bronchitis
Figure 8: Signs and Symptoms of Bronchitis
Figure 9: Referral Pathway for Bronchitis
Figure 10: Algorithm for the Treatment of Patients with Acute Bronchitis
Figure 11: Treatment of Patients with Bronchitis
Figure 12: Bronchitis Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 13: Bronchitis Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 14: Bronchitis Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 15: Bronchitis Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 16: Bronchitis Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 17: Bronchitis Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 18: Bronchitis Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 19: Bronchitis Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 20: Bronchitis Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 21: Bronchitis Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 22: Bronchitis Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 23: Bronchitis Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 24: Bronchitis Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 25: Bronchitis Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 26: Bronchitis Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 27: Bronchitis Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 28: Opportunity and Unmet Need in the Bronchitis Therapeutics Market, 2011
Figure 29: Strategic Competitor Assessment of the Major Marketed Products for Bronchitis, 2011
Figure 30: Bronchitis Therapeutics - Pipeline by Phase of Development, 2011
Figure 31: Technology Trends Analytic Framework of the Bronchitis Therapeutics Pipeline, 2011
Figure 32: Technology Trends Analytic Framework of the Bronchitis Therapeutics Pipeline- Description, 2011
Figure 33: Bronchitis Therapeutics Market - Pipeline by Mechanism of Action, 2011
Figure 34: Bronchitis Therapeutics Market, Clinical Trials by Indication, 2011
Figure 35: Acute Bronchitis Therapeutics Market, Clinical Trials by Country, 2011
Figure 36: Acute Bronchitis Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 37: Acute Bronchitis Therapeutics Market - Clinical Trials by Trial Status, 2011
Figure 38: Acute Bronchitis Therapeutics Market - Clinical Trials by Sponsors, 2011
Figure 39: Acute Bronchitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Figure 40: Chronic Bronchitis Therapeutics Market, Clinical Trials by Country, 2011
Figure 41: Chronic Bronchitis Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 42: Chronic Bronchitis Therapeutics Market - Clinical Trials by Trial Status, 2011
Figure 43: Chronic Bronchitis Therapeutics Market - Clinical Trials by Overall Sponsors, 2011
Figure 44: Chronic Bronchitis Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Figure 45: Chronic Bronchitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Figure 46: COPD Therapeutics Market, Clinical Trials by Country, 2011
Figure 47: COPD Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 48: COPD Therapeutics Market - Clinical Trials by Trial Status, 2011
Figure 49: COPD Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Figure 50: COPD Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Figure 51: Bronchitis Therapeutics Market, Drivers and Barriers, 2011
Figure 52: Implications for Future Market Competition in the Bronchitis Therapeutics Market, 2011
Figure 53: Bronchitis Therapeutics Market, Pipeline by Company, 2011

GlobalData, the industry analysis specialist, has released its new report, “Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global bronchitis market. The report identifies the key trends shaping and driving the global bronchitis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bronchitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Bronchitis Therapeutics Market is Forecast to Show Slow Growth until 2018

GlobalData estimates that the global bronchitis therapeutics market was valued at $5,984m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.9% to reach $6,931m by 2018. The current market is sub-divided into acute bronchitis and chronic bronchitis. The acute bronchitis market is mainly served by generic antibiotics such as azithromycin, clarithromycin, erythromycin, sulfamethoxazole and trimethoprim. The therapies for chronic bronchitis includes drug classes such as bronchodilators, inhaled corticosteroids and combination therapies. The bronchitis therapeutics market has registered high growth of 13.6% during 2005 to 2010. This is due to the growth in the patient population during 2005 - 2010 and the increased uptake of novel products such as Advair/Seretide (fluticasone propionate and salmeterol fixed dose combination), Spiriva (tiotropium) and Symbicort (budesonide 160µg and formoterol fumarate dihydrate 4.5µg).

Bronchitis Therapeutics Market, Global, Forecast ($m), 2005 - 2018

Source: GlobalData, American Lung Association, Centre for Disease Prevention and Control (CDC), Sidney S. Braman. Chronic Cough due to Acute Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines, Chest 2006; 129:95S-103S, Richard P. Wenzel. Acute Bronchitis. New England Journal of Medicine 2006; 355:2125-30, R. de Marco, et al. Trend in the Prevalence of Chronic Bronchitis In Italy Between 1998 and 2010 - Preliminary Results. American Journal of Respiratory and Critical Care Medicine 2011; 183: A1739, National Health Service (NHS), UK, Cerveri, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. European Respiratory Journal 2001; 18:85-92, Linder JA, et al. Antibiotic Treatment of Acute Bronchitis in Smokers: A Systematic Review. Journal of General Internal Medicine 2002; 17(3):230-4.

Symbicort, Spiriva and Advair/ Seretide continue to maintain significant presence in the current bronchitis therapeutics market. Advair is marketed under the brand name Seretide in the EU. During 2010-2018, these brands are on the verge of patent expiry. In the five major European markets, the patent of Seretide will expire in 2013, whereas in the US market, Advair is set to expire in 2011. However, an important aspect to consider is that despite the patent expiry of Advair in 2011, the drug would have no significant value erosion for the next two to three years in the US. Teva Pharmaceutical Industries has cited the presence of regulatory hurdles in the approval of generic version of Advair. Post 2013; genericization of Advair/Seretide, Spiriva and Symbicort would result in a decline in the market valuations. Another major event in the bronchitis therapeutics market during 2010-2018 is the development of novel, once-daily inhalation based therapies which are expected to offer better safety, efficacy and compliance rates in comparison with the existing therapies. It is estimated that these therapies would marginally offset the negative impact of the patent expiries and this would lead to a slow growth in the future market.

GlaxoSmithKline
Novartis AG
AstraZeneca
Bronchitis Pipeline
Merck & Co.
Forest Laboratories, Inc.
Boehringer Ingelheim GmbH
Financial Overview
Almirall, S.A.
Orion Corporation
Rottapharm Madaus
Ache Laboratorios Farmaceuticos S/A